AcelRx Pharmaceuticals Inc. (ACRX)

2.53
0.02 0.80
NASDAQ : Health Technology
Prev Close 2.51
Open 2.45
Day Low/High 2.35 / 2.56
52 Wk Low/High 1.65 / 5.05
Volume 1.97M
Avg Volume 2.79M
Exchange NASDAQ
Shares Outstanding 76.39M
Market Cap 191.75M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

North Korea puts a worrying wrinkle in the markets. We add to 2 portfolio positions.

Stocks Under $10 Weekly Summary

It was a rough week for the portfolio.

Stick With AcelRx Pharmaceuticals Despite Selloff

Unless there is a dilution event around the corner, the selloff is overdone.

Adding to 2 Positions

We'll purchase more shares of Pixelworks and Inovio ahead of their quarterly results next week.

Stocks Under $10 Weekly Summary

We made several trades and price target changes during a mixed week for the portfolio.

Raising Our Price Target on 2 Holdings, Cutting It on One

Sometimes, changing the price target is better than selling (or buying).

Stocks Under $10 Weekly Summary

The portfolio has some high fliers and underperformers last week as we head into the heart of earnings season.

Interesting ACRX Call Options For March 2018

Interesting ACRX Call Options For March 2018

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading today, for the March 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Adding to a Name on Weakness

It's hard to ignore INO's price this far below our cost basis.

A Pharma Pairs Trade

We'll take some profits in AcelRx and lower our cost basis on Inovio.

Stocks Under $10 Weekly Summary

We brought a new name into the portfolio last week as the Fed's comments helped lift the market.

Adding to a Biotech Position

We'll lower our cost basis on Inovio Pharmaceuticals.

Stocks Under $10 Weekly Summary

We made no trades during the holiday-shortened week, but added to our natural hedge today.

Stocks Under $10 Weekly Summary

We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.

Stocks Under $10 Weekly Summary

We exited 2 positions and took some profits during a busy week for the portfolio.

Stocks Under $10 Weekly Summary

We initiated a new position and made several other trades during a week of twists and turns.

Stocks Under $10 Weekly Summary

We initiated 2 new positions in a week dominated by political events.

Adding to AcelRx on Weakness

Shares have dropped to the level we mentioned Friday.

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

Stocks Under $10 Weekly Summary

We scaled further into one position and added a Bullpen name as the market shrugged off geopolitical uncertainties.

Stocks Under $10 Weekly Summary

We exited 3 names last week as stocks continued their run.

Stocks Under $10 Weekly Summary

It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.

Adding a Specialty Pharma Name

AcelRx Pharmaceuticals is another interesting, yet speculative, play.

ACRX: Insiders vs. Shorts

ACRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.

First Week of ACRX September 16th Options Trading

First Week of ACRX September 16th Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

TheStreet Quant Rating: D- (Sell)